SetPoint Medical announced October 28 that a patient had received its implanted neurostimulation system at Beth Israel Deaconess Medical Center in Boston.
The company identified functional neurosurgeon Joshua Aronson as the physician who performed the procedure. Its release described this as the first use of the SetPoint System in Boston, but did not specify the procedure's date or report the patient's outcome.
The system uses a small implanted device to stimulate the left vagus nerve. SetPoint describes its intended patient group as adults with moderately to severely active rheumatoid arthritis who have not responded adequately to, or cannot tolerate, specified prior medicines.
The announcement concerns the expansion of treatment availability, rather than a new clinical trial result. The company's release lists potential risks including surgical pain or infection, hoarseness, bruising, swelling, coughing and throat irritation, and says individual results vary.
SetPoint said Boston joins other U.S. markets offering the system. The announcement provides no basis for predicting an individual patient's response or comparing this hospital's results with other treatment centers.
Sources SetPoint Medical announcement: https://www.prnewswire.com/news-releases/setpoint-medical-announces-first-setpoint-system-procedure-in-boston-at-beth-israel-deaconess-medical-center-302921794.html